Recent AQST News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:08:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 08:04:40 PM
- Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2026 08:01:00 PM
- Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree • GlobeNewswire Inc. • 05/12/2026 01:31:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 09:34:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 09:33:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 09:31:34 PM
- Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Pattern Of Harm: SueWallSt • PR Newswire (US) • 04/30/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/24/2026 09:10:26 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 09:05:43 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 09:00:52 PM
- AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt • PR Newswire (US) • 04/23/2026 01:00:00 PM
- AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/21/2026 01:00:00 PM
- AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/14/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:54:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:54:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:53:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:52:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 07:51:56 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/10/2026 01:56:19 PM
- AQST Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Aquestive Therapeutics, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/07/2026 01:00:00 PM
- AQST Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Aquestive Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm • PR Newswire (US) • 03/31/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:44:46 AM
- Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM

